SCHEMBL4368574

SCHEMBL4368574

NC(=O)[C@H](Cc1ccc(OC(F)(F)F)cc1)NC(=O)c1ccc(OCCC(F)(F)F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.51
ACACB O00763 2/20 0.47
ITGB3 P05106 1/20 0.47
ITGA2B P08514 1/20 0.47
USP30 Q70CQ3 1/20 0.46
PPARG P37231 4/20 0.46
EPHX2 P34913 3/20 0.44
PPARA Q07869 2/20 0.44
GPR132 Q9UNW8 1/20 0.44
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
NR1H4 Q96RI1 1/20 0.42
HPGDS O60760 2/20 0.42
FPR2 P25090 1/20 0.42
TLR7 Q9NYK1 1/20 0.42
CA2 P00918 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA9 Q16790 1/20 0.40
PTPN1 P18031 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4374870 1.00 KLKB1 (0.51) KLKB1ACACBITGB3ITGA2BUSP30
SCHEMBL4368099 0.95 KLKB1 (0.51) KLKB1ACACBITGB3ITGA2BUSP30
SCHEMBL4368718 0.90 ITGB3 (0.56) KLKB1ACACBITGB3ITGA2BUSP30
SCHEMBL4373683 0.88 KLKB1 (0.54) KLKB1ACACBITGB3ITGA2BUSP30
SCHEMBL4367194 0.88 KLKB1 (0.54) KLKB1ACACBITGB3ITGA2BUSP30
SCHEMBL4361537 0.86 KLKB1 (0.59) KLKB1ACACBITGB3ITGA2BUSP30
SCHEMBL4365940 0.85 ITGB3 (0.58) KLKB1ITGB3ITGA2BUSP30PPARG
SCHEMBL4372744 0.85 KLKB1 (0.50) KLKB1ACACBITGB3ITGA2BUSP30
SCHEMBL4369924 0.85 KLKB1 (0.56) KLKB1ACACBITGB3ITGA2BUSP30
SCHEMBL4367205 0.85 KLKB1 (0.54) KLKB1ACACBITGB3ITGA2BUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
EP-1908466-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-04-09 EP disclosed
EP-1908466-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME PTMS, C1S, ACP3 KLKB1 3853/4885ACACB 735/4885ITGB3 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.